{
  "source": "PA-Med-Nec-Dupixent.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2116-21\nProgram Prior Authorization/Medical Necessity\nMedications Dupixent® (dupilumab)\nP&T Approval Date 1/2017, 5/2017, 7/2017, 7/2018, 12/2018, 4/2019, 10/2019, 4/2020, 5/2020,\n6/2020, 6/2021, 12/2021, 2/2022, 7/2022, 11/2022, 3/2023, 7/2023, 3/2024,\n11/2024, 3/2025, 6/2025\nEffective Date 9/1/2025\n1. Background:\nDupixent® (dupilumab) is an interleukin-4 receptor alpha antagonist indicated for treatment of\npatients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is\nnot adequately controlled with topical prescription therapies or when those therapies are not\nadvisable. Dupixent can be used with or without topical corticosteroids. Dupixent is also\nindicated as an add-on maintenance treatment in patients with moderate-to-severe asthma aged\n6 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma,\nas an add-on maintenance treatment in adult and pediatric patients aged 12 years and older\nwith inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP), for the\ntreatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with\neosinophilic esophagitis (EoE), for adult patients with prurigo nodularis (PN), as add-on\nmaintenance treatment of adult patients with inadequately controlled chronic obstructive\npulmonary disease (COPD) and an eosinophilic phenotype, and for the treatment of adult and\npediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who\nremain symptomatic despite H1 antihistamine treatment.\nLimitation of Use:\nDupixent is not for the relief of acute bronchospasm or status asthmaticus.\n2. Coverage Criteriaa:\nA. Atopic Dermatitis\n1. Initial Authorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Diagnosis of moderate-to-severe chronic atopic dermatitis\n-AND-\n(2) History of failure, contraindication, or intolerance t",
    "tion\na. Dupixent will be approved based on all of the following criteria:\n(1) Diagnosis of moderate-to-severe chronic atopic dermatitis\n-AND-\n(2) History of failure, contraindication, or intolerance to two of the following\ntherapeutic classes of topical therapies (document drug, date of trial, and/ or\ncontraindication to medication)^:\n(a) Medium,high, or very-high potency topical corticosteroid [e.g., Elocon\n(mometasone furoate), Synalar (fluocinolone acetonide), Lidex (fluocinonide)]\n© 2025 UnitedHealthcare Services, Inc.\n1\n(b) Topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic\n(tacrolimus)].*\n(c) Eucrisa (crisaborole)*\n-AND-\n(3) Patient is not receiving Dupixent in combination with either of the following for\ntreatment of the same indication:\n(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm)]\n(b) Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib),\nOpzelura (topical ruxolitinib), Cibinqo (abrocitinib)]\n-AND-\n(4) Prescribed by one of the following:\n(a) Dermatologist\n(b) Allergist\n(c) Immunologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Dupixent therapy\n-AND-\n(2) Patient is not receiving Dupixent in combination with either of the following for\ntreatment of the same indication:\n(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm)]\n(b) Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib),\nOpzelura (topical ruxolitinib), Cibinqo (abrocitinib)]\n-AND-\n(3) Prescribed by one of the following:\n(a) Dermatologist\n(b) Allergist\n(c) Immunologist\nAuthorization will be issued for 12 months.\nB. Asthma\n© 2025 UnitedHealthcare Services, Inc.\n2\n1. Initial Authorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Diagnosis of moderate-to-severe asthma\n-AND-\n(2) Classification of asthma as uncontrolled or inadequately controlled",
    "horization\na. Dupixent will be approved based on all of the following criteria:\n(1) Diagnosis of moderate-to-severe asthma\n-AND-\n(2) Classification of asthma as uncontrolled or inadequately controlled as defined by at\nleast one of the following:\n(a) Poor symptom control (e.g., Asthma Control Questionnaire [ACQ] score\nconsistently greater than 1.5 or Asthma Control Test [ACT] score consistently\nless than 20)\n(b) Two or more bursts of systemic corticosteroids for at least 3 days each in the\nprevious 12 months\n(c) Asthma-related emergency treatment (e.g., emergency room visit, hospital\nadmission, or unscheduled physician’s office visit for nebulizer or other urgent\ntreatment)\n(d) Airflow limitation (e.g., after appropriate bronchodilator withhold forced\nexpiratory volume in 1 second [FEV1] less than 80% predicted [in the face of\nreduced FEV1/forced vital capacity [FVC] defined as less than the lower limit\nof normal])\n(e) Patient is currently dependent on oral corticosteroids for the treatment of\nasthma\n-AND-\n(3) One of the following:\n(a) Submission of medical records (e.g., chart notes, laboratory values, etc.)\ndocumenting that asthma is an eosinophilic phenotype as defined by a baseline\n(pre-dupilumab treatment) peripheral blood eosinophil level ≥ 150 cells/μL\n-OR-\n(b) Patient is currently dependent on oral corticosteroids for the treatment of asthma\n-AND-\n(4) Dupixent will be used in combination with one of the following:\n(a) One maximally dosed (appropriately adjusted for age) combination inhaled\ncorticosteroid (ICS)/long-acting beta agonist (LABA) [e.g., Advair/AirDuo\n2\nRespiclick (fluticasone propionate/salmeterol), Symbicort\n(budesonide/formoterol), Breo Ellipta (fluticasone furoate/vilanterol)]\n-OR-\n(b) Combination therapy including both of the following:\n© 2025 UnitedHealthcare Services, Inc.\n3\ni. One maximally dosed (appropriately adjusted for age) ICS product [e.g.,\nciclesonide (Alvesco), mometasone furoate (Asmanex), beclomethasone\ndipropionate (QVAR)]\n-AND-",
    "tedHealthcare Services, Inc.\n3\ni. One maximally dosed (appropriately adjusted for age) ICS product [e.g.,\nciclesonide (Alvesco), mometasone furoate (Asmanex), beclomethasone\ndipropionate (QVAR)]\n-AND-\nii. One additional asthma controller medication [e.g., LABA - olodaterol\n(Striverdi) or indacaterol (Arcapta); leukotriene receptor antagonist –\nmontelukast (Singulair); theophylline]\n-AND-\n(5) Patient is not receiving Dupixent in combination with any of the following for\ntreatment of the same indication:\n(a) Anti-interleukin-5 therapy [e.g., Nucala (mepolizumab), Cinqair (resilizumab),\nFasenra (benralizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]\n-AND-\n(6) Prescribed by one of the following:\n(a) Allergist\n(b) Immunologist\n(c) Pulmonologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Dupixent therapy as demonstrated\nby at least one of the following:\n(a) Reduction in the frequency of exacerbations\n(b) Decreased utilization of rescue medications\n(c) Increase in percent predicted FEV1 from pretreatment baseline\n(d) Reduction in severity or frequency of asthma-related symptoms (e.g.,\nwheezing, shortness of breath, coughing, etc.)\n(e) Reduction in oral corticosteroid requirements\n-AND-\n(2) Dupixent is being used in combination with an ICS-containing maintenance\nmedication [e.g., Advair/AirDuo (fluticasone/salmeterol), Breo Ellipta (fluticasone\n© 2025 UnitedHealthcare Services, Inc.\n4\nfuroate/vilanterol), Symbicort (budesonide/ formoterol), Trelegy Ellipta\n(fluticasone furoate/umeclidinium/vilanterol)].\n-AND-\n(3) Patient is not receiving Dupixent in combination with any of the following for\ntreatment of the same indication:\n(a) Anti-interleukin-5 therapy [e.g., Nucala (mepolizumab), Cinqair (resilizumab),\nFasenra (benralizumab)]\n(b) Anti-IgE therap",
    "mbination with any of the following for\ntreatment of the same indication:\n(a) Anti-interleukin-5 therapy [e.g., Nucala (mepolizumab), Cinqair (resilizumab),\nFasenra (benralizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]\n-AND-\n(4) Prescribed by one of the following:\n(a) Allergist\n(b) Immunologist\n(c) Pulmonologist\nAuthorization will be issued for 12 months.\nC. Chronic Rhinosinusitis with Nasal Polyposis\n1. Initial Authorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP) defined by all\nof the following:\n(a) Two or more of the following symptoms for longer than 12 weeks duration:\ni. Nasal mucopurulent discharge\nii. Nasal obstruction, blockage, or congestion\niii. Facial pain, pressure, and/or fullness\niv. Reduction or loss of sense of smell\n-AND-\n(b) One of the following findings using nasal endoscopy and/or sinus computed\ntomography (CT):\ni. Purulent mucus or edema in the middle meatus or ethmoid regions\nii. Polyps in the nasal cavity or the middle meatus\niii. Radiographic imaging demonstrating mucosal thickening or partial or\ncomplete opacification of paranasal sinuses\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n5\n(c) One of the following:\ni. Presence of bilateral nasal polyposis\nii. Patient has previously required surgical removal of bilateral nasal polyps\n-AND-\n(d) One of the following:\ni. Patient has required prior sinus surgery\nii. Patient has required systemic corticosteroids (e.g., prednisone,\nmethylprednisolone) for CRSwNP in the previous 2 years\niii. Patient has been unable to obtain symptom relief after trial of two of the\nfollowing classes of agents^:\n• Nasal saline irrigations\n• Intranasal corticosteroids (e.g., fluticasone, mometasone,\ntriamcinolone)\n• Antileukotriene agents (e.g., montelukast, zafirlukast, zileuton)\n-AND-\n(2) Patient will receive Dupixent as add-on maint",
    "\n• Intranasal corticosteroids (e.g., fluticasone, mometasone,\ntriamcinolone)\n• Antileukotriene agents (e.g., montelukast, zafirlukast, zileuton)\n-AND-\n(2) Patient will receive Dupixent as add-on maintenance therapy in combination with\nintranasal corticosteroids (e.g., fluticasone, mometasone, triamcinolone).\n-AND-\n(3) Patient is not receiving Dupixent in combination with any of the following for\ntreatment of the same indication:\n(a) Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra (benralizumab),\nNucala (mepolizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]\n-AND-\n(4) Prescribed by one of the following:\n(a) Allergist\n(b) Immunologist\n(c) Otolaryngologist\n(d) Pulmonologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Dupixent will be approved based on all of the following criteria:\n© 2025 UnitedHealthcare Services, Inc.\n6\n(1) Documentation of positive clinical response to Dupixent therapy\n-AND-\n(2) Patient will continue to receive Dupixent as add-on maintenance therapy in\ncombination with intranasal corticosteroids (e.g., fluticasone, mometasone,\ntriamcinolone).\n-AND-\n(3) Patient is not receiving Dupixent in combination with any of the following for\ntreatment of the same indication:\n(a) Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra (benralizumab),\nNucala (mepolizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]\n-AND-\n(4) Prescribed by one of the following:\n(a) Allergist\n(b) Immunologist\n(c) Otolaryngologist\n(d) Pulmonologist\nAuthorization will be issued for 12 months.\nD. Eosinophilic Esophagitis\n1. Initial Authorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Diagnosis of eosinophilic esophagitis\n-AND-\n(2) Patient is experiencing symptoms related to esophageal dysfunction (e.g.,\ndysphagia, food impaction, c",
    "roved based on all of the following criteria:\n(1) Diagnosis of eosinophilic esophagitis\n-AND-\n(2) Patient is experiencing symptoms related to esophageal dysfunction (e.g.,\ndysphagia, food impaction, chest pain that is often centrally located and may not\nrespond to antacids, gastroesophageal reflux disease-like symptoms/refractory\nheartburn, upper abdominal pain)\n-AND-\n(3) Submission of medical records (e.g., chart notes, laboratory values, etc.)\ndocumenting eosinophil-predominant inflammation on esophageal biopsy,\nconsisting of a peak value of ≥15 intraepithelial eosinophils per high power field\n(HPF) (or 60 eosinophils per mm2)\n© 2025 UnitedHealthcare Services, Inc.\n7\n-AND-\n(4) Secondary causes of esophageal eosinophilia have been ruled out\n-AND-\n(5) Mucosal eosinophilia is isolated to the esophagus and symptoms have persisted\nafter an 8-week trial of at least one of the following:b\n(a) Proton pump inhibitors (e.g., pantoprazole, omeprazole)\n(b) Topical (esophageal) corticosteroids (e.g., budesonide, fluticasone)\n-AND-\n(6) Patient is not receiving Dupixent in combination with any of the following for\ntreatment of the same indication:\n(a) Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra (benralizumab),\nNucala (mepolizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]\n-AND-\n(7) Prescribed by one of the following:\n(a) Gastroenterologist\n(b) Allergist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Dupixent therapy as evidenced by\nimprovement of at least one of the following from baseline:\n(a) Symptoms (e.g., dysphagia, chest pain, heartburn)\n(b) Histologic measures (e.g., esophageal intraepithelial eosinophil count)\n(c) Endoscopic measures (e.g., edema, furrows, exudates, rings, strictures)\n-AND-\n(2) Patient is not receiving Dupixent i",
    "n)\n(b) Histologic measures (e.g., esophageal intraepithelial eosinophil count)\n(c) Endoscopic measures (e.g., edema, furrows, exudates, rings, strictures)\n-AND-\n(2) Patient is not receiving Dupixent in combination with any of the following for\ntreatment of the same indication:\n(a) Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra (benralizumab),\nNucala (mepolizumab)]\n© 2025 UnitedHealthcare Services, Inc.\n8\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]\n-AND-\n(3) Prescribed by or in consultation with a gastroenterologist or allergist\nAuthorization will be issued for 12 months.\nE. Prurigo Nodularis\n1. Initial Authorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Diagnosis of prurigo nodularis\n-AND-\n(2) Patient has greater than or equal to 20 nodular lesions\n-AND-\n(3) History of failure, contraindication, or intolerance to previous prurigo nodularis\ntreatment(s) (e.g., topical corticosteroids, topical calcineurin inhibitors, topical\ncapsaicin)\n-AND-\n(4) Patient is not receiving Dupixent in combination with either of the following for\ntreatment of the same indication:\n(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Nemluvio\n(nemolizumab-ilto)]\n(b) Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib),\nOpzelura (topical ruxolitinib), Cibinqo (abrocitinib)]\n-AND-\n(5) Prescribed by one of the following:\n(a) Dermatologist\n(b) Allergist\n(c) Immunologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Dupixent will be approved based on all of the following criteria:\n© 2025 UnitedHealthcare Services, Inc.\n9\n(1) Documentation of positive clinical response to Dupixent therapy\n-AND-\n(2) Patient is not receiving Dupixent in combination with either of the following for\ntreatment of the same indication:\n(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Nemluvio\n(nemolizumab-ilto)]\n(b)",
    "not receiving Dupixent in combination with either of the following for\ntreatment of the same indication:\n(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Nemluvio\n(nemolizumab-ilto)]\n(b) Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib),\nOpzelura (topical ruxolitinib), Cibinqo (abrocitinib)]\n-AND-\n(3) Prescribed by one of the following:\n(a) Dermatologist\n(b) Allergist\n(c) Immunologist\nAuthorization will be issued for 12 months.\nF. Chronic Obstructive Pulmonary Disorder (COPD)\n1. Initial Authorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Diagnosis of COPD\n-AND-\n(2) Submission of medical records (e.g., chart notes) documenting all of the following:\n(a) Post-bronchodilator forced expiratory volume (FEV ) / forced vital capacity\n1\n(FVC) ratio less than 0.7\n(b) Post-bronchodilator FEV % predicted greater than or equal to 30% and less\n1\nthan or equal to 70%\n(c) Patient has an eosinophilic phenotype defined by a baseline (pre-dupilumab\ntreatment) peripheral blood eosinophil level ≥ 300 cells/μL\n-AND-\n(3) Uncontrolled or inadequately controlled COPD demonstrated by both of the\nfollowing:\n(a) One of the following:\n© 2025 UnitedHealthcare Services, Inc.\n10\ni. Two or more COPD exacerbations in the previous year requiring treatment\nwith systemic corticosteroids and/or antibiotics\nii. One or more COPD exacerbation(s) that resulted in hospitalization or\nobservation for over 24 hours in an emergency department or urgent care\nfacility in the past year\n-AND-\n(b) COPD exacerbation(s) occurred while receiving maintenance therapy with one\nof the following:\ni. Triple therapy with a long-acting muscarinic antagonist (LAMA), long-\nacting beta agonist (LABA), and inhaled corticosteroid (ICS) (e.g., Breztri\nAerosphere, Trelegy Ellipta)\nii. Dual therapy with a LAMA and LABA (e.g., Anoro Ellipta, Bevespi\nAerosphere, Stiolto Respimat) and a failure, contraindication, or intolerance\nto an inhaled corticosteroid (ICS)\n",
    ", Trelegy Ellipta)\nii. Dual therapy with a LAMA and LABA (e.g., Anoro Ellipta, Bevespi\nAerosphere, Stiolto Respimat) and a failure, contraindication, or intolerance\nto an inhaled corticosteroid (ICS)\n-AND-\n(4) Symptoms of chronic productive cough for at least 3 months in the past year\n-AND-\n(5) Dupixent will be used as add-on maintenance therapy in combination with one of\nthe following:\n(a) Triple therapy with a long-acting muscarinic antagonist (LAMA), long-acting\nbeta agonist (LABA), and inhaled corticosteroid (ICS) (e.g., Breztri Aerosphere,\nTrelegy Ellipta)\n(b) Dual therapy with a LAMA and LABA (e.g., Anoro Ellipta, Bevespi\nAerosphere, Stiolto Respimat) and a failure, contraindication, or intolerance to\nan inhaled corticosteroid (ICS)\n-AND-\n(6) Patient is not receiving Dupixent in combination with any of the following for\ntreatment of the same indication:\n(a) Anti-interleukin-5 therapy [e.g., Nucala (mepolizumab), Cinqair (resilizumab),\nFasenra (benralizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]\n-AND-\n(7) Prescribed by one of the following:\n(a) Allergist\n(b) Immunologist\n© 2025 UnitedHealthcare Services, Inc.\n11\n(c) Pulmonologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Documentation of a positive clinical response to Dupixent therapy as demonstrated\nby at least one of the following:\n(a) Reduction in the frequency of COPD exacerbations\n(b) Increase in percent predicted FEV1 from pretreatment baseline\n(c) Reduction in severity or frequency of COPD-related symptoms (e.g., dyspnea,\nwheezing, cough, sputum volume, decrease in sputum purulence)\n(d) Reduction in oral corticosteroid requirements\n-AND-\n(2) Dupixent is being used add-on maintenance therapy in combination with one of the\nfollowing:\n(a) Triple therapy with a long-acting muscarinic antagonist (LAMA), long-acting\nbeta agon",
    "irements\n-AND-\n(2) Dupixent is being used add-on maintenance therapy in combination with one of the\nfollowing:\n(a) Triple therapy with a long-acting muscarinic antagonist (LAMA), long-acting\nbeta agonist (LABA), and inhaled corticosteroid (ICS) (e.g., Breztri Aerosphere,\nTrelegy Ellipta)\n(b) Dual therapy with a long-acting muscarinic antagonist (LAMA) and long-acting\nbeta agonist (LABA) (e.g., Anoro Ellipta, Bevespi Aerosphere, Stiolto\nRespimat) and a failure, contraindication, or intolerance to an inhaled\ncorticosteroid (ICS)\n-AND-\n(3) Patient is not receiving Dupixent in combination with any of the following for\ntreatment of the same indication:\n(a) Anti-interleukin-5 therapy [e.g., Nucala (mepolizumab), Cinqair (resilizumab),\nFasenra (benralizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]\n-AND-\n(4) Prescribed by one of the following:\n(a) Allergist\n(b) Immunologist\n(c) Pulmonologist\nAuthorization will be issued for 12 months.\nG. Chronic Spontaneous Urticaria\n© 2025 UnitedHealthcare Services, Inc.\n12\n1. Initial Authorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Diagnosis of chronic spontaneous urticaria\n-AND-\n(2) One of the following:\n(a) Patient remains symptomatic despite at least a 2-week trial of, or history of\ncontraindication or intolerance to, two H1-antihistamines [e.g., Allegra\n(fexofenadine), Benadryl (diphenhydramine), Claritin (loratadine)]^\n-OR-\n(b) Patient remains symptomatic despite at least a 2-week trial of, or history of\ncontraindication or intolerance to both of the following taken in\ncombination^:\ni. A second generation H1-antihistamine [e.g., Allegra (fexofenadine),\nClaritin (loratadine), Zyrtec (cetirizine)]\n-AND-\nii. One of the following:\n• A different second generation H1-antihistamine [e.g., Allegra\n(fexofenadine), Claritin (loratadine), Zyrtec (cetirizine)]\n• A first generation H1-antihistamine [e.g., Benadryl\n(diph",
    "f the following:\n• A different second generation H1-antihistamine [e.g., Allegra\n(fexofenadine), Claritin (loratadine), Zyrtec (cetirizine)]\n• A first generation H1-antihistamine [e.g., Benadryl\n(diphenhydramine), Chlor-Trimeton (chlorpheniramine), Vistaril\n(hydroxyzine)]\n• An H2-antihistamine [e.g., Pepcid (famotidine), Tagamet HB\n(cimetidine), Zantac (ranitidine)]\n• A leukotriene modifier [e.g., Singulair (montelukast)]\n-AND-\n(3) Patient is not receiving Dupixent in combination with Xolair (omalizumab) for\ntreatment of the same indication\n-AND-\n(4) Prescribed by one of the following:\n(a) Allergist\n(b) Dermatologist\n(c) Immunologist\n© 2025 UnitedHealthcare Services, Inc.\n13\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Dupixent therapy (e.g., reduction in\nexacerbations, itch severity, hives)\n-AND-\n(2) Patient is not receiving Dupixent in combination with Xolair (omalizumab) for\ntreatment of the same indication\n-AND-\n(3) Prescribed by one of the following:\n(a) Allergist\n(b) Dermatologist\n(c) Immunologist\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\nb For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.\n^Tried/failed alternative(s) are supported by FDA labeling.\n* Elidel, Protopic/tacrolimus ointment, and Eucrisa require prior authorization.\nTable 1: Relative potencies of topical corticosteroids3\nClass Drug Dosage Form Strength\n(%)\nAugmented betamethasone Ointment, gel 0.05\ndipropionate\nVery high\nClobetasol propionate Cream, foam, ointment 0.05\npotency\nDiflorasone diacetate Ointment 0.05\nHalobetasol propionate Cream, ointment 0.05\nAmcinonide Cream, lotion, ointment 0.1\nAugmented betamethasone Cr",
    "obetasol propionate Cream, foam, ointment 0.05\npotency\nDiflorasone diacetate Ointment 0.05\nHalobetasol propionate Cream, ointment 0.05\nAmcinonide Cream, lotion, ointment 0.1\nAugmented betamethasone Cream, lotion 0.05\ndipropionate\nBetamethasone dipropionate Cream, foam, ointment, solution 0.05\nHigh Potency Desoximetasone Cream, ointment 0.25\nDesoximetasone Gel 0.05\nDiflorasone diacetate Cream 0.05\nFluocinonide Cream, gel, ointment, solution 0.05\nHalcinonide Cream, ointment 0.1\n© 2025 UnitedHealthcare Services, Inc.\n14\nMometasone furoate Ointment 0.1\nTriamcinolone acetonide Cream, ointment 0.5\nBetamethasone valerate Cream, foam, lotion, ointment 0.1\nClocortolone pivalate Cream 0.1\nDesoximetasone Cream 0.05\nFluocinolone acetonide Cream, ointment 0.025\nMedium\nFlurandrenolide Cream, ointment, lotion 0.05\npotency\nFluticasone propionate Cream 0.05\nFluticasone propionate Ointment 0.005\nMometasone furoate Cream, lotion 0.1\nTriamcinolone acetonide Cream, ointment, lotion 0.1\nHydrocortisone butyrate Cream, ointment, solution 0.1\nLower-\nHydrocortisone probutate Cream 0.1\nmedium\nHydrocortisone valerate Cream, ointment 0.2\npotency\nPrednicarbate Cream 0.1\nAlclometasone dipropionate Cream, ointment 0.05\nLow potency Desonide Cream, gel, foam, ointment 0.05\nFluocinolone acetonide Cream, solution 0.01\nDexamethasone Cream 0.1\nLowest\nHydrocortisone Cream, lotion, ointment, solution 0.25, 0.5, 1\npotency\nHydrocortisone acetate Cream, ointment 0.5-1\n© 2025 UnitedHealthcare Services, Inc.\n15\nTable 2: Low, medium and high daily doses of inhaled corticosteroids6\nAdults and adolescents (12 years of age and older)\nDrug Daily dose (mcg)\nLow Medium High\nBeclometasone dipropionate (CFC) 200-500 >500-1000 >1000\nBeclometasone dipropionate (HFA) 100-200 >200-400 >400\nBudesonide DPI 200-400 >400-800 >800\nCiclesonide (HFA) 80-160 >160-320 >320\nFluticasone furoate (DPI) 100 n.a 200\nFluticasone propionate (DPI) 100-250 >250-500 >500\nFluticasone propionate (HFA) 100-250 >250-500 >500\nMometasone furoate 11",
    "Ciclesonide (HFA) 80-160 >160-320 >320\nFluticasone furoate (DPI) 100 n.a 200\nFluticasone propionate (DPI) 100-250 >250-500 >500\nFluticasone propionate (HFA) 100-250 >250-500 >500\nMometasone furoate 110-220 >220-440 >440\nTriamcinolone acetonide 400-1000 >1000-2000 >2000\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class\n• Supply limitations may be in place\n4. References:\n1. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo\nin atopic dermatitis. N Engl J Med. 2016 Sep 30.\n2. Dupixent® [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc. April 2025.\n3. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2024.\nAvailable at http://www.ginasthma.org. Accessed April 23, 2025.\n4. Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe\nuncontrolled asthma. N Engl J Med. 2018; 378:2486-96.\n5. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-\ndependent severe asthma. N Engl J Med. 2018; 378:2475-85.\n6. Buchheit, Hamilos DL. Chronic rhinosinusitis with nasal polyposis: management and prognosis.\nUpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed on April 23,\n2025.\n7. Holbrook EH. Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis.\nUpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed on April 23,\n2025.\n8. Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory\nSociety/American Thoracic Society guideline. Eur Respir J. 2020 Jan 2;55(1):1900588. doi:\n10.1183/13993003.00588-2019. PMID: 31558662\n9. Dellon ES, Muir AB, Katzka DA, et al. ACG Clinical Guideline: D",
    "Society/American Thoracic Society guideline. Eur Respir J. 2020 Jan 2;55(1):1900588. doi:\n10.1183/13993003.00588-2019. PMID: 31558662\n9. Dellon ES, Muir AB, Katzka DA, et al. ACG Clinical Guideline: Diagnosis and Management of\nEosinophilic Esophagitis. Am J Gastroenterol. 2025;120(1):31-59.\ndoi:10.14309/ajg.0000000000003194\n10. Boguniewicz M, Levy ML, Eichenfield LF, et al. Managing Childhood and Adolescent Atopic\nDermatitis in Primary Care: A US Expert Group Consensus. The Journal of Pediatrics: Clinical\nPractice. 2024; 14: 200121, ISSN 2950-5410. https://doi.org/10.1016/j.jpedcp.2024.200121.\n© 2025 UnitedHealthcare Services, Inc.\n16\nProgram Prior Authorization/Medical Necessity - Dupixent (dupilumab)\nChange Control\n1/2017 New program.\n5/2017 Updated background and references. Dupixent approved on 3/28/2017.\n7/2017 Updated criteria to differentiate based on physician assessment of\nseverity. Eucrisa added as required treatment in moderate severity\ndisease. Added criteria allowing treatment if disease history required\ntreatment with systemic immunosuppressants. Added criteria for\npatients previously on therapy. Added sample pack language.\nRemoved medical record submission requirement while adding\nrequirement for medication trial or contraindication documentation.\nAdded corticosteroid potency table as reference.\n7/2018 Annual review with no change to coverage criteria. Updated reference.\n12/2018 Updated background and formatting and added criteria for new\nindication for moderate-to-severe asthma.\n4/2019 Updated background and criteria for updated indication of adolescent\natopic dermatitis. Removed criteria regarding history of systemic\nimmunosuppressant for atopic dermatitis use as allowance for initial\napproval as no longer critical with market availability surpassing 2\nyears.\n10/2019 Updated Dupixent® (dupilumab) background and criteria for new\nindication for CRSwNP. Updated references.\n4/2020 Updated criteria for atopic dermatitis requiring failure of two topicals\n",
    "years.\n10/2019 Updated Dupixent® (dupilumab) background and criteria for new\nindication for CRSwNP. Updated references.\n4/2020 Updated criteria for atopic dermatitis requiring failure of two topicals\nfor all severities of atopic dermatitis\n5/2020 Updated criteria for clarification without change to clinical intent\n6/2020 Updated background and criteria to include new indication for\nmoderate-to-severe atopic dermatitis in children aged 6 to 11 years.\nAligned specialist requirement across indications for initial\nauthorizations and reauthorization.\n6/2021 Annual review with no change to criteria. Updated background, drug\nexamples, and references.\n12/2021 Updated background and criteria to include expanded indication of\nmoderate to severe eosinophilic or oral corticosteroid dependent asthma\nto patients aged 6 years and older. Updated references.\n2/2022 Removed bypass of initial authorization for patients currently on\ntherapy with Dupixent for all indications. Updated initial authorization\nperiod to 12 months. Updated agents not to be used in combination with\nDupixent for all indications. Removed age requirement from atopic\ndermatitis and asthma coverage criteria. Updated coverage criteria for\nCRSwNP. Updated references. Added footnote to support FDA\nlabeled first line requirements.\n7/2022 Added clinical criteria for eosinophilic esophagitis. Removed footnote\nregarding sample initiation from the asthma as this no longer applies.\nUpdated background, state mandate, and references.\n11/2022 Updated criteria to include new indication for prurigo nodularis.\nUpdated reference.\n3/2023 Updated not used in combination criteria for atopic dermatitis and\nprurigo nodularis.\n7/2023 Updated coverage criteria for severe asthma to align with GINA &\nERS/ATS guidelines. Added/updated examples of ICS-containing\n© 2025 UnitedHealthcare Services, Inc.\n17\nmaintenance medications and removed requirement that peripheral\nblood eosinophil level must be within 6 weeks. Updated references.\n3/2024 Cl",
    "of ICS-containing\n© 2025 UnitedHealthcare Services, Inc.\n17\nmaintenance medications and removed requirement that peripheral\nblood eosinophil level must be within 6 weeks. Updated references.\n3/2024 Clarified topical steroid potency in atopic dermatitis with no change to\nclinical intent or coverage criteria. Removed weight requirement from\nEosinophilic Esophagitis criteria. Updated state mandate footnote,\nbackground and reference.\n11/2024 Added criteria to include new indication for chronic obstructive\npulmonary disorder. Updated background and reference.\n3/2025 Increased authorizations for eosinophilic esophagitis to 12 months.\n6/2025 Added criteria to include new indication for chronic spontaneous\nurticaria. Updated approval duration for prurigo nodularis. Updated\ncoverage criteria for concomitant use. Added Nemluvio to the list of\nexamples of biologic immunomodulators for prurigo nodularis. Updated\nbackground and reference.\n© 2025 UnitedHealthcare Services, Inc.\n18"
  ]
}